# Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

> **NCT00664599** · PHASE2 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 20 (actual)

## Conditions studied

- Behcet's Syndrome

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cytotoxic Combination

## Key facts

- **NCT ID:** NCT00664599
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2008-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664599, "Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00664599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*